Mercy Medical Center | GI Research

Research site

(Unclaimed)

Location

301 Street Paul Place, POB 718, Baltimore, Maryland, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Trastuzumab

Atezolizumab

Bevacizumab

BMS-790052

Daclatasvir

Ribavirin

Letrozole

Carboplatin

Obeticholic Acid

Parent organization

This site is a part of Mercy Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 161 total trials

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling

NASH

Cirrhosis, Liver

Drug: Resmetirom

Drug: Placebo

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling

Non-alcoholic Steatohepatitis (NASH)

Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Placebo

Drug: ALN-HSD

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Enrolling

Carcinoma, Hepatocellular

Drug: Tiragolumab

Other: Placebo

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Active, not recruiting

Breast Cancer

Drug: Trastuzumab Emtansine

Drug: Placebo

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Drug: Palbociclib

Drug: Giredestrant

Locations recently updated

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Active, not recruiting

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Drug: Fulvestrant

Drug: Dexamethasone Mouth Rinse

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in particip...

Active, not recruiting

Carcinoma, Hepatocellular

Drug: Bevacizumab

Drug: Atezolizumab

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting

Colitis, Ulcerative

Drug: Placebo

Drug: JNJ-77242113

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting

Hepatocellular Carcinoma

Drug: Nofazinlimab (CS1003)+Lenvatinib

Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, f...

Active, not recruiting

Breast Cancer

Drug: Tobemstomig

Drug: Nab-Paclitaxel

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting

HER2-Positive Primary Breast Cancer

Residual Invasive Breast Cancer

Drug: DS-8201a

Drug: T-DM1

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease...

Active, not recruiting

Primary Sclerosing Cholangitis

Drug: Placebo Matched to Elafibranor 80 mg

Drug: Placebo Matched to Elafibranor 120 mg

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in...

Active, not recruiting

Early Breast Cancer

Drug: Ribociclib

Other: Endocrine Therapy

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling

Hepatic Impairment

Compensated Cirrhosis

Drug: Seladelpar 10 mg or less

Drug: Seladelpar 10 mg

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associ...

Enrolling

Alcohol Associated Hepatitis

Drug: INT-787

Drug: Placebo

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes (CENTRICITY)

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting

Nonalcoholic Steatohepatitis (NASH)

Type 2 Diabetes

Drug: Placebo

Drug: HTD1801

IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Inco...

Enrolling

Primary Biliary Cholangitis

Drug: Placebo

Drug: Seladelpar 10 mg

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer underg...

Enrolling

Stage IIA Breast Cancer

Stage IA Breast Cancer

Other: Laboratory Biomarker Analysis

Radiation: Intraoperative Radiation Therapy

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of es...

Active, not recruiting

Breast Cancer

Other: Placebo

Drug: Letrozole

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Palbociclib